PROGRAM CHAIR
Amy McMichael, MD
Professor of Dermatology
Wake Forest School of Medicine
Winston-Salem, NC
PROGRAM OVERVIEW
This enduring case-based activity is designed to assist dermatologists and advanced practice providers in identifying patients with alopecia areata (AA) who may benefit from Janus kinase (JAK) inhibitor therapy. This program will examine factors that contribute to the decision to prescribe JAK inhibitors, review the latest clinical data on their safety and efficacy, and outline strategies to individualize treatment for patients with severe AA using a shared decision-making approach.
TARGET AUDIENCE
This activity is intended for global dermatologists, nurse practitioners, and physician assistants who treat patients with alopecia areata.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Determine which patients with alopecia areata would benefit from treatment with Janus Kinase (JAK) inhibitors based on patient and disease characteristics
- Individualize treatment for patients with alopecia areata using a shared decision-making approach, setting expectations based on long-term patterns of clinical response
- Evaluate clinical data on the safety and efficacy and mechanisms of Janus kinase (JAK) inhibitors for the treatment of patients with alopecia areata
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Amy McMichael, MD | Discloses that she has received research funds from Incyte and Sun Pharmaceutical, as well as honoraria and/or consulting fees from Eli Lilly, Janssen Pharmaceuticals, Pfizer, Arcutis Biotherapeutics, Almirall, AbbVie, CeraVe, Galderma, Bristol Myers Squibb, Sanofi-Regeneron, UCB, Procter & Gamble, REVIAN, Johnson & Johnson, L’Oréal, Leo Pharma, and Nutrafol. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kia Jones, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 15, 2023
EXPIRATION DATE: November 15, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Amy McMichael, MD
Professor of Dermatology
Wake Forest School of Medicine
Winston-Salem, NC
PROGRAM OVERVIEW
This enduring case-based activity is designed to assist dermatologists and advanced practice providers in identifying patients with alopecia areata (AA) who may benefit from Janus kinase (JAK) inhibitor therapy. This program will examine factors that contribute to the decision to prescribe JAK inhibitors, review the latest clinical data on their safety and efficacy, and outline strategies to individualize treatment for patients with severe AA using a shared decision-making approach.
TARGET AUDIENCE
This activity is intended for global dermatologists, nurse practitioners, and physician assistants who treat patients with alopecia areata.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Determine which patients with alopecia areata would benefit from treatment with Janus Kinase (JAK) inhibitors based on patient and disease characteristics
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Amy McMichael, MD | Discloses that she has received research funds from Incyte and Sun Pharmaceutical, as well as honoraria and/or consulting fees from Eli Lilly, Janssen Pharmaceuticals, Pfizer, Arcutis Biotherapeutics, Almirall, AbbVie, CeraVe, Galderma, Bristol Myers Squibb, Sanofi-Regeneron, UCB, Procter & Gamble, REVIAN, Johnson & Johnson, L’Oréal, Leo Pharma, and Nutrafol. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kia Jones, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: November 15, 2023
EXPIRATION DATE: November 15, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Amy McMichael, MD
Professor of Dermatology
Wake Forest School of Medicine
Winston-Salem, NC
CONTRIBUTING FACULTY
Jorge Larrondo, MD
Department of Dermatology
Clínica Alemana-Universidad del Desarrollo
Santiago, Chile
PROGRAM OVERVIEW
This enduring case-based activity is designed to assist dermatologists and advanced practice providers in identifying patients with alopecia areata (AA) who may benefit from Janus kinase (JAK) inhibitor therapy. This program will examine factors that contribute to the decision to prescribe JAK inhibitors, review the latest clinical data on their safety and efficacy, and outline strategies to individualize treatment for patients with severe AA using a shared decision-making approach.
TARGET AUDIENCE
This activity is intended for global dermatologists, nurse practitioners, and physician assistants who treat patients with alopecia areata.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Determine which patients with alopecia areata would benefit from treatment with Janus Kinase (JAK) inhibitors based on patient and disease characteristics
- Evaluate clinical data on the safety and efficacy and mechanisms of Janus kinase (JAK) inhibitors for the treatment of patients with alopecia areata
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Amy McMichael, MD | Discloses that she has received research funds from Incyte and Sun Pharmaceutical, as well as honoraria and/or consulting fees from Eli Lilly, Janssen Pharmaceuticals, Pfizer, Arcutis Biotherapeutics, Almirall, AbbVie, CeraVe, Galderma, Bristol Myers Squibb, Sanofi-Regeneron, UCB, Procter & Gamble, REVIAN, Johnson & Johnson, L’Oréal, Leo Pharma, and Nutrafol. |
| Jorge Larrondo, MD | Has nothing to disclose |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kia Jones, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg. Physical, Dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: November 15, 2023
EXPIRATION DATE: November 15, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
